Skip to Content
Print Share

Generic Lyrica CR Availability

See also: Generic Lyrica

Lyrica CR is a brand name of pregabalin, approved by the FDA in the following formulation(s):

LYRICA CR (pregabalin - tablet, extended release;oral)

  • Manufacturer: PF PRISM CV
    Approval date: October 11, 2017
    Strength(s): 82.5MG [RLD], 165MG [RLD], 330MG [RLD]

Has a generic version of Lyrica CR been approved?

No. There is currently no therapeutically equivalent version of Lyrica CR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lyrica CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Solid pharmaceutical compositions containing pregabalin
    Patent 10,022,447
    Issued: July 17, 2018
    Assignee(s): Warner-Lambert Company LLC

    A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

    Patent expiration dates:

    • November 2, 2026
      ✓ 
      Patent use: TREATMENT OF POSTHERPETIC NEURALGIA
    • November 2, 2026
      ✓ 
      Patent use: TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
  • Patent 10022447*

    Patent expiration dates:

    • May 2, 2027
  • Gamma amino butyric acid analogs and optical isomers
    Patent 6,197,819
    Issued: March 6, 2001
    Inventor(s): Silverman; Richard B. & Andruszkiewicz; Ryszard
    Assignee(s): Northwestern University

    A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.

    Patent expiration dates:

    • December 30, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 30, 2019
      ✓ 
      Pediatric exclusivity
  • Solid pharmaceutical compositions containing pregabalin
    Patent 8,945,620
    Issued: February 3, 2015
    Assignee(s): Warner-Lambert Company LLC

    A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

    Patent expiration dates:

    • November 2, 2026
      ✓ 
      Patent use: TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
      ✓ 
      Drug product
    • November 2, 2026
      ✓ 
      Patent use: TREATMENT OF POSTHERPETIC NEURALGIA
      ✓ 
      Drug product
    • May 2, 2027
      ✓ 
      Pediatric exclusivity
  • Solid pharmaceutical compositions containing pregabalin
    Patent 9,144,559
    Issued: September 29, 2015
    Assignee(s): Warner-Lambert Company LLC

    A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

    Patent expiration dates:

    • November 2, 2026
      ✓ 
      Drug product
    • May 2, 2027
      ✓ 
      Pediatric exclusivity
  • Isobutylgaba and its derivatives for the treatment of pain
    Patent RE41920
    Issued: November 9, 2010
    Inventor(s): Singh; Lakhbir
    Assignee(s): Warner-Lambert Company LLC

    The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.

    Patent expiration dates:

    • December 30, 2018
      ✓ 
      Patent use: TREATMENT OF POSTHERPETIC NEURALGIA
    • December 30, 2018
      ✓ 
      Patent use: TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
    • June 30, 2019
      ✓ 
      Pediatric exclusivity

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • October 11, 2020 - NEW PRODUCT
    • April 11, 2021 - PEDIATRIC EXCLUSIVITY

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Add to My Med List

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide